Trials / Active Not Recruiting
Active Not RecruitingNCT02343991
Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound
A Study to Evaluate the Safety and Feasibility of Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound With Intravenous Ultrasound Contrast Agents in the Treatment of Brain Tumours With Doxorubicin
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- InSightec · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety of BBB disruption using transcranial MRI-guided focused ultrasound in conjunction with an intravenous ultrasound contrast agent to increase the accumulation of doxorubicin in brain tumours and the adjacent brain using the ExAblate Transcranial system (220 kHz). Data will be collected to establish the basic safety of this type of treatment as the basis for later studies to evaluate its clinical efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Transcranial ExABlate | MR Guided Focused Ultrasound |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2015-01-22
- Last updated
- 2025-05-01
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT02343991. Inclusion in this directory is not an endorsement.